WallStreetZenWallStreetZen

NASDAQ: APTO
Aptose Biosciences Inc Stock

$0.76-0.04 (-5%)
Updated Jun 21, 2024
APTO Price
$0.76
Fair Value Price
$1.21
Market Cap
$12.40M
52 Week Low
$0.74
52 Week High
$5.58
P/E
-0.12x
P/B
90.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$47.17M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
92.4
Operating Cash Flow
-$45M
Beta
0.88
Next Earnings
Aug 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

APTO Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

APTO ($0.76) is undervalued by 37.35% relative to our estimate of its Fair Value price of $1.21 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
APTO ($0.76) is significantly undervalued by 37.35% relative to our estimate of its Fair Value price of $1.21 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
APTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APTO due diligence checks available for Premium users.

Be the first to know about important APTO news, forecast changes, insider trades & much more!

APTO News

Valuation

APTO fair value

Fair Value of APTO stock based on Discounted Cash Flow (DCF)
Price
$0.76
Fair Value
$1.21
Undervalued by
37.35%
APTO ($0.76) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APTO ($0.76) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

APTO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.12x
Industry
-5.75x
Market
30.75x

APTO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
90.48x
Industry
6.2x
APTO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

APTO's financial health

Profit margin

Revenue
$0.0
Net Income
-$9.6M
Profit Margin
0%
APTO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$12.8M
Liabilities
$12.7M
Debt to equity
92.4
APTO's short-term liabilities ($12.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APTO's short-term assets ($11.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APTO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
APTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$11.8M
Investing
-$2.0M
Financing
$11.8M
APTO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

APTO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
APTO$12.40M-5.00%-0.12x90.48x
XTLB$12.18M-2.40%-7.45x5.49x
IMRN$12.07M-1.40%-4.76x1.03x
MNPR$12.06M+2.53%-1.33x1.61x
PIRS$12.00M+2.94%-0.76x0.55x

Aptose Biosciences Stock FAQ

What is Aptose Biosciences's quote symbol?

(NASDAQ: APTO) Aptose Biosciences trades on the NASDAQ under the ticker symbol APTO. Aptose Biosciences stock quotes can also be displayed as NASDAQ: APTO.

If you're new to stock investing, here's how to buy Aptose Biosciences stock.

What is the 52 week high and low for Aptose Biosciences (NASDAQ: APTO)?

(NASDAQ: APTO) Aptose Biosciences's 52-week high was $5.58, and its 52-week low was $0.74. It is currently -86.38% from its 52-week high and 2.7% from its 52-week low.

How much is Aptose Biosciences stock worth today?

(NASDAQ: APTO) Aptose Biosciences currently has 16,309,393 outstanding shares. With Aptose Biosciences stock trading at $0.76 per share, the total value of Aptose Biosciences stock (market capitalization) is $12.40M.

Aptose Biosciences stock was originally listed at a price of $3,040.61 in Dec 31, 1997. If you had invested in Aptose Biosciences stock at $3,040.61, your return over the last 26 years would have been -99.98%, for an annualized return of -27.31% (not including any dividends or dividend reinvestments).

How much is Aptose Biosciences's stock price per share?

(NASDAQ: APTO) Aptose Biosciences stock price per share is $0.76 today (as of Jun 21, 2024).

What is Aptose Biosciences's Market Cap?

(NASDAQ: APTO) Aptose Biosciences's market cap is $12.40M, as of Jun 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aptose Biosciences's market cap is calculated by multiplying APTO's current stock price of $0.76 by APTO's total outstanding shares of 16,309,393.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.